熱門資訊> 正文
Tarsus通过2亿美元融资承诺对现有债务进行再融资
2024-04-23 20:51
- Tarsus Pharmaceuticals (NASDAQ:TARS) secured $200M in committed capital from funds associated with Pharmakon Advisors, LP.
- Tarsus has elected to draw $75M on the closing date, April 19, 2024, with the remaining $125M of committed capital available at the company’s option in three tranches through specified time windows, the last ending in December 2025.
- Net proceeds to the company at closing will be approximately $40M.
- The new five-year interest-only credit facility with Pharmakon provides for three potential additional loan tranches, to be drawn at the company’s option, in principal amounts up to $25M, $50M and $50M, respectively, the latter two tranches available upon achievement of certain revenue thresholds.
- Source: Press Release
More on Tarsus Pharmaceuticals
- Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
- Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript
- Tarsus Pharmaceuticals stock dips after pricing $100M securities offering
- Tarsus reports positive Phase 2 results for Lyme disease product
- Seeking Alpha’s Quant Rating on Tarsus Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
